Cel Sci Corporation (CVM)

[lightrock]

Ok, not to argue, but then we need to resolve this...

https://clinicaltrials.gov/ct2/show/NCT01265849?term=multikine&draw=2&rank=3

Primary Outcome Measures :
Overall Survival (OS) in LI + CIZ + SOC vs. SOC [ Time Frame: 3 year ]
OS will be assessed using Kaplan-Meier life-table and compared using a logrank test and confirmed further with tumor stage location and geographic stratified log rank tests. The unstratified logrank test constitutes the primary analysis. A two-sided p-value of 0.05 or less will be considered statistically significant for comparing the two groups. Interim analyses will be performed throughout the study to assess safety, sample size and futility.